Back to Results

Myomo Inc (MYO)

Myomo, Inc. is a healthcare equipment and supplies company focused on wearable medical robotics. The company develops and manufactures myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and other international markets. Its product line includes MyoPro, a myoelectric-controlled upper limb brace designed to support a weak or paralyzed arm and assist daily activities, along with MyoPro 2, which adds control technology, configuration software, a user interface, and a pop-out battery for longer use. Myomo also offers MyoPro2+, MyoGames, and the MyoPro 2x Video Library, as well as MyoCare, a post-delivery support program for clients, therapists, and referral sources. The company serves adults and adolescents with conditions related to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. Founded in 2004, Myomo is headquartered in Burlington, Massachusetts, and its common stock trades on the NYSE under the symbol MYO.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-MYO
$1.21
26.0% Upside
Undervalued
$4.42
358.5% Upside
Bargain
Fair
—
—
—
0.0%
August 11, 2026
-2.5x
4.1x
0.9x
34.775 M
40.359 M
35.3%
69.5%
-3.7
—
102.1%
Valuation • Fair Value

Myomo Inc (NYSE-MYO) Fair Value by Valuation Model

Compare the primary fair value estimate for Myomo Inc (NYSE-MYO) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$1.21

Estimated upside of 26.0% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$0.78

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

$1.37

Earnings power value estimate.

Comps Fair Value

$1.33

Comparable-company valuation reference.

Analyst Price Target

$4.42

Analysts imply upside of 358.5%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Myomo Inc (NYSE-MYO) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Myomo Inc (NYSE-MYO)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

41.21 M

Current operating scale indicator.

Revenue Forecast

44.5 M

Forward revenue estimate.

EBITDA

-13.046 M

Current operating profitability reference.

EBITDA Forecast

-9.3 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Myomo Inc (NYSE-MYO) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Myomo Inc (NYSE-MYO)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

2

Weak quality score that deserves closer review.

Beneish M-Score

-1.57

Higher caution zone on this screen.

Altman Z-Score

-3.7

Lower score that deserves closer risk review.

FCF / Net Income

102.1%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Myomo Inc (NYSE-MYO). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Myomo Inc (NYSE-MYO)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 11, 2026

Days to Earnings

21

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Myomo Inc (NYSE-MYO), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Myomo Inc (NYSE-MYO) Stock Forecast & Technical Outlook

Review Myomo Inc (NYSE-MYO) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Myomo Inc (NYSE-MYO) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Sell

The 1-hour technical read for Myomo Inc (NYSE-MYO) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Myomo Inc (NYSE-MYO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Myomo Inc (NYSE-MYO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Myomo Inc (NYSE-MYO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Myomo Inc (NYSE-MYO)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Myomo Inc (NYSE-MYO) has a Strong Buy consensus, with 3 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 3
Hold 0
Sell 0
FAQ • Fast Investor Answers

Myomo Inc (NYSE-MYO) Stock FAQ

Quick answers about Myomo Inc (NYSE-MYO) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$1.21
Estimated upside 26.0%
Valuation Rating
Undervalued
Estimated upside of 26.0%
Analyst Target
$4.42
Implied upside 358.5%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Myomo Inc (NYSE-MYO) is $1.21. This implies an estimated upside of 26.0% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 26.0% versus the current market price.

The available analyst price target for Myomo Inc (NYSE-MYO) is $4.42. The analyst target implies estimated upside of 358.5%.

The current financial health read for Myomo Inc (NYSE-MYO) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Myomo Inc (NYSE-MYO) is August 11, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Myomo Inc (NYSE-MYO) is -2.5x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Myomo Inc is 34.775 M.

The current enterprise value listed for Myomo Inc is 40.359 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Myomo Inc is NYSE-MYO, and the stock is listed on NYSE.

Myomo Inc (NYSE-MYO) is listed on NYSE.

The current debt-to-total-capital ratio listed for Myomo Inc is 35.3%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Myomo Inc is 69.5%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks on NYSE View more

Abbott Laboratories (ABT) Abbott Laboratories (ABT)
Stryker Corporation (SYK) Stryker Corporation (SYK)
Medtronic PLC (MDT) Medtronic PLC (MDT)
Boston Scientific Corp (BSX) Boston Scientific Corp (BSX)
Edwards Lifesciences Corp (EW) Edwards Lifesciences Corp (EW)
Becton Dickinson and Co (BDX) Becton Dickinson and Co (BDX)
Alcon AG (ALC) Alcon AG (ALC)
ResMed Inc (RMD) ResMed Inc (RMD)
Koninklijke Philips NV ADR (PHG) Koninklijke Philips NV ADR (PHG)
STERIS plc (STE) STERIS plc (STE)
Zimmer Biomet Holdings Inc (ZBH) Zimmer Biomet Holdings Inc (ZBH)
Solventum Corp (SOLV) Solventum Corp (SOLV)
Smith & Nephew SNATS Inc (SNN) Smith & Nephew SNATS Inc (SNN)
Penumbra Inc (PEN) Penumbra Inc (PEN)
Baxter International Inc (BAX) Baxter International Inc (BAX)
Globus Medical (GMED) Globus Medical (GMED)
Glaukos Corp (GKOS) Glaukos Corp (GKOS)
Teleflex Incorporated (TFX) Teleflex Incorporated (TFX)
Bausch + Lomb Corp (BLCO) Bausch + Lomb Corp (BLCO)
Envista Holdings Corp (NVST) Envista Holdings Corp (NVST)
Haemonetics Corporation (HAE) Haemonetics Corporation (HAE)
Integer Holdings Corp (ITGR) Integer Holdings Corp (ITGR)
Butterfly Network, Inc (BFLY) Butterfly Network, Inc (BFLY)
Enovis Corp (ENOV) Enovis Corp (ENOV)